MECHELEN, BELGIUM--(Marketwired - May 17, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG)
that its Board of Directors created 648,490 warrants under a new warrant
for the benefit of employees, directors and independent consultants
Company and its subsidiaries.
On 16 May 2013, the Board of Directors of Galapagos approved the "Warrant
2013" within the framework of the authorized capital. Under this warrant
648,490 warrants were created, subject to acceptances.
The warrants created under Warrant Plan 2013 were offered on 16 May 2013,
to employees of Galapagos and its subsidiaries and in secondary order
directors and independent consultants. The offer of warrants to
been pre-approved by the Ordinary General Shareholders' Meeting
30 April 2013.
The warrants have an exercise term of eight years as of the date of the
and have an exercise price of EUR19.38 (the average closing price of the
Euronext Brussels during the thirty days preceding date of the offer).
warrants are not transferable and can in principle not be exercised prior
end of the third calendar year after the calendar year in which they
granted to the beneficiaries. Each warrant gives the right to subscribe
new Galapagos share. Should the warrants be exercised, Galapagos will
the listing of the resulting new shares on a regulated stock market.
warrants as such will not be listed on any stock market.
To date, Galapagos' total share capital amounts to EUR160,474,357.19;
number of securities conferring voting rights is 29,665,159, which is
total number of voting rights (the "denominator"), and all securities
voting rights and all voting rights are of the same category. The total
of rights (warrants) to subscribe to not yet issued securities conferring
rights is 3,123.368, which equals the total number of voting rights
result from the exercise of these warrants. Galapagos does not
convertible bonds or shares without voting rights outstanding.
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized in
with a large pipeline of four clinical, seven pre-clinical, and 30
small-molecule and antibody programs in cystic fibrosis,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases,
enter Phase 2b studies in RA and Phase 2 studies in Crohn's disease.
Galapagos signed a worldwide license agreement whereby AbbVie
responsible for further development and commercialization after Phase
Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus
psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
2012). GLPG0187 is a novel integrin receptor antagonist currently in a
1b patient study in metastasis. GLPG0974 is the first inhibitor of GPR43
evaluated clinically for the treatment of IBD; this program is currently
Proof of Concept Phase 2 study.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information at:
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Galapagos creates new warrant plan:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE